Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 04, 2022

SELL
$1.57 - $3.33 $787,942 - $1.67 Million
-501,874 Reduced 7.31%
6,363,945 $11 Million
Q1 2022

May 06, 2022

SELL
$2.76 - $4.64 $365,873 - $615,092
-132,563 Reduced 1.89%
6,865,819 $22.1 Million
Q4 2021

Feb 08, 2022

SELL
$4.09 - $7.16 $118,683 - $207,768
-29,018 Reduced 0.41%
6,998,382 $30.8 Million
Q3 2021

Nov 09, 2021

SELL
$5.8 - $8.02 $783,034 - $1.08 Million
-135,006 Reduced 1.88%
7,027,400 $42 Million
Q1 2021

May 03, 2021

BUY
$7.67 - $13.77 $1.03 Million - $1.85 Million
134,178 Added 1.91%
7,162,406 $61.5 Million
Q4 2020

Feb 11, 2021

BUY
$12.07 - $17.95 $262,498 - $390,376
21,748 Added 0.31%
7,028,228 $85.1 Million
Q3 2020

Nov 02, 2020

SELL
$14.16 - $19.45 $1.94 Million - $2.67 Million
-137,139 Reduced 1.92%
7,006,480 $114 Million
Q2 2020

Aug 07, 2020

SELL
$6.97 - $17.12 $8.48 Million - $20.8 Million
-1,217,151 Reduced 14.56%
7,143,619 $107 Million
Q1 2020

Apr 30, 2020

BUY
$5.79 - $11.83 $1.22 Million - $2.49 Million
210,788 Added 2.59%
8,360,770 $60.7 Million
Q4 2019

Feb 06, 2020

BUY
$3.9 - $6.16 $1.27 Million - $2.01 Million
325,528 Added 4.16%
8,149,982 $48.6 Million
Q3 2019

Oct 29, 2019

BUY
$3.01 - $4.49 $18.6 Million - $27.8 Million
6,193,417 Added 379.72%
7,824,454 $33.1 Million
Q2 2019

Jul 29, 2019

BUY
$2.8 - $4.14 $2.08 Million - $3.08 Million
744,447 Added 83.97%
1,631,037 $6.26 Million
Q1 2019

Apr 30, 2019

BUY
$2.35 - $4.19 $2.07 Million - $3.69 Million
880,370 Added 14153.86%
886,590 $3.67 Million
Q4 2018

Feb 08, 2019

SELL
$2.17 - $3.8 $147 - $258
-68 Reduced 1.08%
6,220 $13,000
Q3 2018

Oct 15, 2018

BUY
$3.0 - $4.05 $18,864 - $25,466
6,288 New
6,288 $24,000

Others Institutions Holding CGEN

About COMPUGEN LTD


  • Ticker CGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 86,624,600
  • Market Cap $131M
  • Description
  • Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tu...
More about CGEN
Track This Portfolio

Track Nikko Asset Management Americas, Inc. Portfolio

Follow Nikko Asset Management Americas, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nikko Asset Management Americas, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Nikko Asset Management Americas, Inc. with notifications on news.